Laura I Stirrat1, James R O'Reilly2, Sarah M Barr1, Ruth Andrew2, Simon C Riley1, Alexander F Howie3, Maria Bowman4, Roger Smith4, John G Lewis5, Fiona C Denison1, Shareen Forbes6, Jonathan R Seckl2, Brian R Walker6, Jane E Norman1, Rebecca M Reynolds7. 1. MRC Centre for Reproductive Health, University of Edinburgh, United Kingdom; Tommy's Centre for Maternal and Fetal Health, University of Edinburgh, United Kingdom. 2. University/BHF Centre for Cardiovascular Science, University of Edinburgh, United Kingdom. 3. MRC Centre for Reproductive Health, University of Edinburgh, United Kingdom. 4. Mothers and Babies Unit, University of Newcastle, Australia. 5. Canterbury Health Laboratories, Christchurch, New Zealand. 6. Tommy's Centre for Maternal and Fetal Health, University of Edinburgh, United Kingdom; University/BHF Centre for Cardiovascular Science, University of Edinburgh, United Kingdom. 7. MRC Centre for Reproductive Health, University of Edinburgh, United Kingdom; Tommy's Centre for Maternal and Fetal Health, University of Edinburgh, United Kingdom; University/BHF Centre for Cardiovascular Science, University of Edinburgh, United Kingdom. Electronic address: R.Reynolds@ed.ac.uk.
Abstract
BACKGROUND: The maternal hypothalamic-pituitary-adrenal-axis (HPAA) undergoes dramatic activation during pregnancy. Increased cortisol and corticotrophin-releasing-hormone (CRH) associate with low birthweight and preterm labor. In non-pregnant obesity, the HPAA is activated but circulating cortisol levels are normal or lower than in lean women. We hypothesized that maternal cortisol levels would be lower in obese pregnancy, and would associate with increased fetal size and length of gestation. METHOD: Fasting serum cortisol was measured at 16, 28 and 36 weeks gestation and at 3-6 months postpartum in 276 severely obese and 135 lean women. In a subset of obese (n=20) and lean (n=20) we measured CRH, hormones that regulate bioavailable cortisol (corticosteroid-binding-globulin, estradiol, estriol, and progesterone). Urinary glucocorticoid metabolites were measured in pregnant (obese n=6, lean n=5) and non-pregnant (obese n=7, lean n=7) subjects. RESULTS: Maternal cortisol and HPAA hormones were lower in obese pregnancy. Total urinary glucocorticoid metabolites increased significantly in lean pregnancy, but not in obese. Lower maternal cortisol in obese tended to be associated with increased birthweight (r=-0.13, p=0.066). In obese, CRH at 28 weeks correlated inversely with gestational length (r=-0.49, p=0.04), and independently predicted gestational length after adjustment for confounding factors (mean decrease in CRH of -0.25 pmol/L (95% CI -0.45 to -0.043 pmol/L) per/day increase in gestation). CONCLUSION: In obese pregnancy, lower maternal cortisol without an increase in urinary glucocorticoid clearance may indicate a lesser activation of the HPAA than in lean pregnancy. This may offer a novel mechanism underlying increased birthweight and longer gestation in obese pregnancy.
BACKGROUND: The maternal hypothalamic-pituitary-adrenal-axis (HPAA) undergoes dramatic activation during pregnancy. Increased cortisol and corticotrophin-releasing-hormone (CRH) associate with low birthweight and preterm labor. In non-pregnant obesity, the HPAA is activated but circulating cortisol levels are normal or lower than in lean women. We hypothesized that maternal cortisol levels would be lower in obese pregnancy, and would associate with increased fetal size and length of gestation. METHOD: Fasting serum cortisol was measured at 16, 28 and 36 weeks gestation and at 3-6 months postpartum in 276 severely obese and 135 lean women. In a subset of obese (n=20) and lean (n=20) we measured CRH, hormones that regulate bioavailable cortisol (corticosteroid-binding-globulin, estradiol, estriol, and progesterone). Urinary glucocorticoid metabolites were measured in pregnant (obese n=6, lean n=5) and non-pregnant (obese n=7, lean n=7) subjects. RESULTS: Maternal cortisol and HPAA hormones were lower in obese pregnancy. Total urinary glucocorticoid metabolites increased significantly in lean pregnancy, but not in obese. Lower maternal cortisol in obese tended to be associated with increased birthweight (r=-0.13, p=0.066). In obese, CRH at 28 weeks correlated inversely with gestational length (r=-0.49, p=0.04), and independently predicted gestational length after adjustment for confounding factors (mean decrease in CRH of -0.25 pmol/L (95% CI -0.45 to -0.043 pmol/L) per/day increase in gestation). CONCLUSION: In obese pregnancy, lower maternal cortisol without an increase in urinary glucocorticoid clearance may indicate a lesser activation of the HPAA than in lean pregnancy. This may offer a novel mechanism underlying increased birthweight and longer gestation in obese pregnancy.
Authors: Keith M Godfrey; Rebecca M Reynolds; Susan L Prescott; Moffat Nyirenda; Vincent W V Jaddoe; Johan G Eriksson; Birit F P Broekman Journal: Lancet Diabetes Endocrinol Date: 2016-10-12 Impact factor: 32.069
Authors: Shannon L Gillespie; Lisa M Christian; Angela D Alston; Pamela J Salsberry Journal: Psychoneuroendocrinology Date: 2017-06-15 Impact factor: 4.905
Authors: Christine H Naya; Claudia M Toledo-Corral; Thomas Chavez; Deborah Lerner; Nathana Lurvey; Sandrah P Eckel; Alicia K Peterson; Brendan H Grubbs; Genevieve F Dunton; Carrie V Breton; Theresa M Bastain Journal: Int J Obes (Lond) Date: 2021-10-30 Impact factor: 5.551
Authors: Eunice H Chin; Kim L Schmidt; Kaitlyn M Martel; Chi Kin Wong; Jordan E Hamden; William T Gibson; Kiran K Soma; Julian K Christians Journal: PLoS One Date: 2017-03-16 Impact factor: 3.240
Authors: Laura I Stirrat; Bram G Sengers; Jane E Norman; Natalie Z M Homer; Ruth Andrew; Rohan M Lewis; Rebecca M Reynolds Journal: J Clin Endocrinol Metab Date: 2018-02-01 Impact factor: 5.958
Authors: Laura I Stirrat; Jamie J Walker; Ksenia Stryjakowska; Natalie Jones; Natalie Z M Homer; Ruth Andrew; Jane E Norman; Stafford L Lightman; Rebecca M Reynolds Journal: Clin Endocrinol (Oxf) Date: 2018-01-29 Impact factor: 3.478
Authors: Laura I Stirrat; George Just; Natalie Z M Homer; Ruth Andrew; Jane E Norman; Rebecca M Reynolds Journal: Sci Rep Date: 2017-08-31 Impact factor: 4.379
Authors: Katarzyna Kosicka; Anna Siemiątkowska; Agata Szpera-Goździewicz; Mariola Krzyścin; Grzegorz H Bręborowicz; Franciszek K Główka Journal: Endocrine Date: 2018-04-02 Impact factor: 3.633